PDCD1 and neoplasm: Recently, a novel PD-1-blocking nanobody (PD-1 Nb20) in combination with a tumor-specific dendritic cell (DC)/tumor fusion cell (FC) vaccine was found to effectively enhance the in vitro cytotoxicity of CD8+ T-cells to kill cancer cells, including NSCLCs [32].